Skip to main content
SpringerLink
Log in
Book cover

Atlas of Atherosclerosis pp 179–191Cite as

The Newer Coronary Risk Factors

  • Chapter

  • 122 Accesses

Abstract

Although the traditional coronary risk factors have included blood pressure, cholesterol, and cigarette smoking, several other factors are now being considered. This chapter provides a sampling of some of these “newer” risk factors, particularly those that have a biologic basis. The major categories to be considered are hematologic, newer lipid particles and their metabolic considerations, vitamins and homocysteine, and aspects of glucose metabolism.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279: 1477–1482.

    Google Scholar 

  2. Meade TW, Brozovic M, Chakrabarti RR, et al.: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986, 2: 533–537.

    Article  PubMed  CAS  Google Scholar 

  3. Ridker PM, Vaughn DE, Stampfer MJ, et al.: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341: 1165–1168.

    Article  PubMed  CAS  Google Scholar 

  4. Thompson SG, Kienast J, Pyke SDM, et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635–641.

    Article  PubMed  CAS  Google Scholar 

  5. Gebara OCE, Mittleman MA, Sutherland P, et al.: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995, 91: 1952–1958.

    Article  PubMed  CAS  Google Scholar 

  6. Juhan-Vague I, Alessi MC: Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993, 70: 138–143.

    PubMed  CAS  Google Scholar 

  7. Willich SN, Levy D, Rocco MB, et al.: Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987, 60: 801–806.

    Article  PubMed  CAS  Google Scholar 

  8. Muller JE, Tofler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79: 733–743.

    Article  PubMed  CAS  Google Scholar 

  9. Schaefer EJ, Lamon-Fava S, Jenner JL, et al.: Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994, 271: 999–1003.

    Article  PubMed  CAS  Google Scholar 

  10. Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995, 273: 1269–1273.

    Article  PubMed  CAS  Google Scholar 

  11. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336: 973–979.

    Article  PubMed  CAS  Google Scholar 

  12. Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C- reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100: 230–235.

    Article  PubMed  CAS  Google Scholar 

  13. Steering Committee of the Physicians’ Health Study Research Group. Final report of the aspirin component of the ongoing Physician’s’ Health Study. N Engl J Med 1989, 321: 129–135.

    Article  Google Scholar 

  14. Peto R, Gray R, Collins R, et al.: Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988, 296: 313–316.

    Article  CAS  Google Scholar 

  15. Smith SC, Jr., Blair SN, Criqui MH, et al.: Consensus Panel Statement: Preventing heart attack and death in patients with coronary disease. Circulation 1995, 92: 2–4.

    Article  PubMed  Google Scholar 

  16. Hennekens CH, Dyken ML, Fuster V: Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals • from the American Heart Association. Circulation 1997, 96: 2751–2753.

    Article  PubMed  CAS  Google Scholar 

  17. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329–1339.

    Article  Google Scholar 

  18. Austin MA, Breslow JL, Hennekens CH, et al.: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260: 1917–1921.

    Article  PubMed  CAS  Google Scholar 

  19. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276: 875–881.

    Article  PubMed  CAS  Google Scholar 

  20. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97: 1029–1036.

    Article  PubMed  CAS  Google Scholar 

  21. Wilson PWF, Myers RH, Larson MG, et al.: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. JAMA 1994, 272: 1666–1671.

    CAS  Google Scholar 

  22. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 1996, 16: 1250–1255.

    Article  CAS  Google Scholar 

  23. Gofman JW, Young W, Tandy R: Ischemic heart disease arthrosclerosis, and longevity. Circulation 1966, 34: 679–697.

    Article  PubMed  CAS  Google Scholar 

  24. Buring JE, O’Connor GT, Goldhaber SZ, et al.: Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992, 85: 22–29.

    Article  PubMed  CAS  Google Scholar 

  25. Stampfer MJ, Hennekens CH, Manson JE, et al.: Vitamin E consumption and risk of coronary heart disease in women. N Engl J Med 1993, 328: 1444 1449.

    Google Scholar 

  26. Rimm EB, Stampfer MJ, Ascherio A: Vitamin E consumption and risk of coronary heart disease in men. N Engl J Med 1993, 328: 1450–1456.

    CAS  Google Scholar 

  27. Steinberg D: A critical look at the evidence for the oxidation of LDL in atherogenesis. Atherosclerosis 1997, 131(Suppl)S5–S7.

    Article  PubMed  CAS  Google Scholar 

  28. Alpha-tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330: 1029–1035.

    Google Scholar 

  29. Boushey CJ, Beresford SAS, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995, 274: 1049–1057.

    Article  PubMed  CAS  Google Scholar 

  30. Selhub J, Jacques PF, Bostom AG, et al.: Association between plasma homocysteine and extracranial carotid stenosis. N Engl J Med 1995, 332: 286–291.

    Article  PubMed  CAS  Google Scholar 

  31. Selhub J, Jacques PF, Wilson PWF, et al.: Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 1993, 270: 2693–2698.

    Article  PubMed  CAS  Google Scholar 

  32. Jacques PF, Selhub J, Bostom AG et al.: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999, 340: 1449–1454.

    Article  PubMed  CAS  Google Scholar 

  33. Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2: 131–141.

    Article  PubMed  CAS  Google Scholar 

  34. Meigs JB, D’Agostino RB, Wilson PWF et al.: Risk variable clustering in the insulin resistance syndrome. Diabetes 1997, 46: 1594–1600.

    Article  PubMed  CAS  Google Scholar 

  35. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994, 43: 960–967.

    Article  PubMed  CAS  Google Scholar 

  36. UK Prospective Diabetes Study (UKPDS) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352: 837–853.

    Article  Google Scholar 

Download references

Authors
  1. Peter W. F. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Boston University School of Medicine, Boston, Massachusetts, USA

    Peter W. F. Wilson MD (Professor of Medicine, Director of Laboratories) (Professor of Medicine, Director of Laboratories)

  2. Framingham Heart Study, Framingham, Massachusetts, USA

    Peter W. F. Wilson MD (Professor of Medicine, Director of Laboratories) (Professor of Medicine, Director of Laboratories)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wilson, P.W.F. (2000). The Newer Coronary Risk Factors. In: Wilson, P.W.F. (eds) Atlas of Atherosclerosis. Current Medicine Group, London. https://doi.org/10.1007/978-1-4757-9310-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9310-9_10

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-4757-9312-3

  • Online ISBN: 978-1-4757-9310-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation